

# Giancarlo Comi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5740539/publications.pdf>

Version: 2024-02-01

368  
papers

39,644  
citations

4388

86  
h-index

3106

187  
g-index

388  
all docs

388  
docs citations

388  
times ranked

22397  
citing authors

#	ARTICLE	IF	CITATIONS
1	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , 2022, 269, 933-944.	3.6	10
2	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1034-1040.	3.0	37
3	CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 608-619.	3.0	13
4	Fitbeat: COVID-19 estimation based on wristband heart rate using a contrastive convolutional auto-encoder. <i>Pattern Recognition</i> , 2022, 123, 108403.	8.1	26
5	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. <i>Neurology</i> , 2022, 98, .	1.1	31
6	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 535-542.	3.3	8
7	COVID-19 Severity in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	57
8	Risk of Getting COVID-19 in People With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	31
9	Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 105-114.	3.0	1
10	Comparing natural history of early and late onset pediatric multiple sclerosis. <i>Annals of Neurology</i> , 2022, , .	5.3	6
11	Intensive Neurorehabilitation and Gait Improvement in Progressive Multiple Sclerosis: Clinical, Kinematic and Electromyographic Analysis. <i>Brain Sciences</i> , 2022, 12, 258.	2.3	6
12	Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a. <i>European Journal of Neurology</i> , 2022, 29, 2024-2035.	3.3	6
13	The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103757.	2.0	10
14	Visual Evoked Potentials to Monitor Myelin Cuprizone-Induced Functional Changes. <i>Frontiers in Neuroscience</i> , 2022, 16, 820155.	2.8	10
15	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. <i>Neurology</i> , 2022, 98, e1626-e1636.	1.1	7
16	Researching COVID-19 in progressive MS requires a globally coordinated, multi-disciplinary and multi-stakeholder approach—perspectives from the International Progressive MS Alliance. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732210991.	1.0	0
17	A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103909.	2.0	4
18	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5â€‰years of follow-up in the DAYBREAK open-label extension trial. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1944-1962.	3.0	16

#	ARTICLE	IF	CITATIONS
19	Repetitive Transcranial Magnetic Stimulation With H-Coil Coupled With Cycling for Improving Lower Limb Motor Function After Stroke: An Exploratory Study. <i>Neuromodulation</i> , 2021, 24, 916-922.	0.8	7
20	Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 21-34.	2.8	6
21	Role of B Cells in Multiple Sclerosis and Related Disorders. <i>Annals of Neurology</i> , 2021, 89, 13-23.	5.3	123
22	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021, 27, 430-438.	3.0	19
23	Multiple Sclerosis Data Alliance – A global multi-stakeholder collaboration to scale-up real world data research. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102634.	2.0	11
24	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102673.	2.0	20
25	Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , 2021, 27, 347-359.	3.0	41
26	The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , 2021, 27, 331-346.	3.0	26
27	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110195.	3.5	48
28	Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.1	36
29	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 780-789.	5.3	370
30	DOP53 Pregnancy outcomes in the ozanimod clinical development program in relapsing multiple sclerosis, Ulcerative Colitis, and Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S088-S089.	1.3	14
31	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 51, 102844.	2.0	19
32	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 726.	9.0	26
33	Spinal Fluid Myeloid Microvesicles Predict Disease Course in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 90, 253-265.	5.3	9
34	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	3.7	86
35	067â€¦Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials. , 2021, , .		0
36	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. <i>European Journal of Neurology</i> , 2021, 28, 3722-3730.	3.3	12

#	ARTICLE	IF	CITATIONS
37	The 4â€Holeâ€Board Test for Assessment of Longâ€Term Spatial Memory in Mice. <i>Current Protocols</i> , 2021, 1, e228.	2.9	6
38	Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5Âmg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies. <i>Advances in Therapy</i> , 2021, 38, 4975-4985.	2.9	14
39	Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732199085.	1.0	3
40	Apparatus design and behavioural testing protocol for the evaluation of spatial working memory in mice through the spontaneous alternation T-maze. <i>Scientific Reports</i> , 2021, 11, 21177.	3.3	40
41	Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e1870-e1885.	1.1	168
42	Structural connectivity in multiple sclerosis and modeling of disconnection. <i>Multiple Sclerosis Journal</i> , 2020, 26, 220-232.	3.0	28
43	Imaging correlates of hand motor performance in multiple sclerosis: A multiparametric structural and functional MRI study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 233-244.	3.0	19
44	Changes in functional and structural brain connectome along the Alzheimerâ€™s disease continuum. <i>Molecular Psychiatry</i> , 2020, 25, 230-239.	7.9	78
45	Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis. <i>Neurotherapeutics</i> , 2020, 17, 208-217.	4.4	28
46	Large vessel occlusion stroke due to dislodged aortic valve calcification revealed by imaging and histopathology. <i>Journal of the Neurological Sciences</i> , 2020, 408, 116573.	0.6	2
47	Italian consensus on treatment of spasticity in multiple sclerosis. <i>European Journal of Neurology</i> , 2020, 27, 445-453.	3.3	20
48	No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon Î²-1a. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101891.	2.0	4
49	A new electrophysiological non-invasive method to assess retinocortical conduction time in the Dark Agouti rat through the simultaneous recording of electroretinogram and visual evoked potential. <i>Documenta Ophthalmologica</i> , 2020, 140, 245-255.	2.2	2
50	Upper limb motor evoked potentials as outcome measure in progressive multiple sclerosis. <i>Clinical Neurophysiology</i> , 2020, 131, 401-405.	1.5	13
51	Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis. <i>BMC Neurology</i> , 2020, 20, 364.	1.8	1
52	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 988-997.	10.2	64
53	COVID-19 in people with multiple sclerosis: A global data sharing initiative. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1157-1162.	3.0	50
54	Teaching NeurolImages: Osteolytic intraosseous meningioma causing transcalvarial herniation. <i>Neurology</i> , 2020, 95, e1110-e1111.	1.1	0

#	ARTICLE	IF	CITATIONS
55	Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation. <i>Molecules</i> , 2020, 25, 5403.	3.8	12
56	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2020, 383, 546-557.	27.0	358
57	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. <i>Brain</i> , 2020, 143, 2637-2652.	7.6	56
58	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. <i>Journal of the Neurological Sciences</i> , 2020, 417, 117064.	0.6	1
59	Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 27, 135245852096037.	3.0	4
60	Neuro-Retina Might Reflect Alzheimer's Disease Stage. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1455-1468.	2.6	16
61	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. <i>Brain</i> , 2020, 143, 3013-3024.	7.6	53
62	Functional evolution of visual involvement in experimental autoimmune encephalomyelitis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732096347.	1.0	7
63	Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102572.	2.0	36
64	The Danger of Walking with Socks: Evidence from Kinematic Analysis in People with Progressive Multiple Sclerosis. <i>Sensors</i> , 2020, 20, 6160.	3.8	3
65	The window of opportunity for treatment of progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , 2020, 33, 262-270.	3.6	27
66	Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. <i>Neurology and Therapy</i> , 2020, 9, 443-457.	3.2	4
67	Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. <i>Neurological Sciences</i> , 2020, 41, 1647-1650.	1.9	48
68	Long-term remission of tumefactive relapsing multiple sclerosis after alemtuzumab rescue treatment in an adolescent patient. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102061.	2.0	2
69	Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. <i>Neurological Sciences</i> , 2020, 41, 2843-2851.	1.9	7
70	Leukocyte Counts and Ratios Are Predictive of Stroke Outcome and Hemorrhagic Complications Independently of Infections. <i>Frontiers in Neurology</i> , 2020, 11, 201.	2.4	33
71	Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease. <i>Journal of Neurology</i> , 2020, 267, 2272-2280.	3.6	26
72	Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. <i>Drug Safety</i> , 2020, 43, 635-643.	3.2	20

#	ARTICLE	IF	CITATIONS
73	Human-Centered Design Strategies for Device Selection in mHealth Programs: Development of a Novel Framework and Case Study. JMIR MHealth and UHealth, 2020, 8, e16043.	3.7	31
74	Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19. Journal of Medical Internet Research, 2020, 22, e19992.	4.3	155
75	Functional and structural plasticity following action observation training in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1472-1487.	3.0	26
76	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Multiple Sclerosis Journal, 2019, 25, 1255-1262.	3.0	37
77	Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2019, 25, 968-979.	3.0	12
78	Emotional outcomes in clinically isolated syndrome and early phase multiple sclerosis: a systematic review and meta-analysis. Journal of Psychosomatic Research, 2019, 124, 109761.	2.6	17
79	Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e591.	6.0	9
80	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1009-1020.	10.2	191
81	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1021-1033.	10.2	184
82	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. Journal of Neurology, 2019, 266, 3098-3107.	3.6	1
83	Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 29, 168-174.	2.0	94
84	Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 33, 75-77.	2.0	13
85	Expanding the spectrum of genes responsible for hereditary motor neuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1171-1179.	1.9	30
86	Engaging across dimensions of diversity: A cross-national perspective on mHealth tools for managing relapsing remitting and progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 32, 123-132.	2.0	34
87	Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy". Annals of Neurology, 2019, 86, 324-324.	5.3	4
88	Concurrence of NMOSD and ALS in a patient with hexanucleotide repeat expansions of C9orf72. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 449-452.	1.7	1
89	Multispectral MRI with Dual Fluorinated Probes to Track Mononuclear Cell Activity in Mice. Radiology, 2019, 291, 351-357.	7.3	36
90	Survival prediction models in motor neuron disease. European Journal of Neurology, 2019, 26, 1143-1152.	3.3	23

#	ARTICLE	IF	CITATIONS
91	Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. <i>Annals of Neurology</i> , 2019, 85, 606-610.	5.3	30
92	Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , 2019, 18, 155-164.	10.2	63
93	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , 2019, 40, 155-165.	1.9	59
94	Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 157-167.	2.0	94
95	Added value of multimodal MRI to the clinical diagnosis of primary progressive aphasia variants. <i>Cortex</i> , 2019, 113, 58-66.	2.4	13
96	Brain and cord imaging features in neuromyelitis optica spectrum disorders. <i>Annals of Neurology</i> , 2019, 85, 371-384.	5.3	66
97	Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. <i>Neurology</i> , 2019, 92, e733-e741.	1.1	57
98	The Multiple Sclerosis Care Unit. <i>Multiple Sclerosis Journal</i> , 2019, 25, 627-636.	3.0	90
99	Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 57-59.	2.0	1
100	Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 204-216.	3.0	33
101	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. <i>Multiple Sclerosis Journal</i> , 2019, 25, 565-573.	3.0	9
102	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 399-407.	3.0	38
103	Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 801-810.	3.0	17
104	Cognitive reserve, cognition, and regional brain damage in MS: A 2%-year longitudinal study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 372-381.	3.0	40
105	Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 819-827.	3.0	46
106	The CSF p-tau181/A $\beta$ 242 Ratio Offers a Good Accuracy in Vivo in the Differential Diagnosis of Alzheimer's Dementia. <i>Current Alzheimer Research</i> , 2019, 16, 587-595.	1.4	17
107	Cervical Cord T1-weighted Hypointense Lesions at MR Imaging in Multiple Sclerosis: Relationship to Cord Atrophy and Disability. <i>Radiology</i> , 2018, 288, 234-244.	7.3	40
108	Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628561775336.	3.5	45



#	ARTICLE	IF	CITATIONS
109	<scp>ECTRIMS</scp>/<scp>EAN</scp> guideline on the pharmacological treatment of people with multiple sclerosis. European Journal of Neurology, 2018, 25, 215-237.	3.3	147
110	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 96-120.	3.0	458
111	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurology, The, 2018, 17, 133-142.	10.2	98
112	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	10.2	4,605
113	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876064.	1.0	32
114	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	13.7	684
115	Bi-hemispheric repetitive transcranial magnetic stimulation for upper limb motor recovery in chronic stroke: A feasibility study. Brain Stimulation, 2018, 11, 932-934.	1.6	4
116	Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. Multiple Sclerosis Journal, 2018, 24, 167-174.	3.0	18
117	The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. Multiple Sclerosis Journal, 2018, 24, 535-539.	3.0	15
118	Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment. Multiple Sclerosis Journal, 2018, 24, 459-471.	3.0	105
119	Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1183-1195.	3.0	54
120	Can pharmacological manipulation of LTP favor the effects of motor rehabilitation in multiple sclerosis?. Multiple Sclerosis Journal, 2018, 24, 902-907.	3.0	5
121	Fast progressive lower motor neuron disease is an ALS variant: A two-centre tract of interest-based MRI data analysis. Neurolmage: Clinical, 2018, 17, 145-152.	2.7	35
122	Safety and efficacy of cladribine tablets in patients with relapsing&#x2013;remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple Sclerosis Journal, 2018, 24, 1594-1604.	3.0	227
123	Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients. Neurological Sciences, 2018, 39, 373-376.	1.9	11
124	040&#x2013;An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A17.1-A17.	1.9	1
125	Letter to the Editor Regarding: A Comprehensive Review on Copemyl&#x2122;. Neurology and Therapy, 2018, 7, 385-390.	3.2	1
126	The role of clinical and neuroimaging features in the diagnosis of CADASIL. Journal of Neurology, 2018, 265, 2934-2943.	3.6	25



#	ARTICLE	IF	CITATIONS
127	039â€¦Rates of lymphopenia in years 1â€“4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A16.2-A16.	1.9	3
128	067â€¦Efficacy of cladribine tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the clarity and onward studies. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A27.2-A28.	1.9	0
129	Neuromyelitis optica spectrum disorder and multiple sclerosis in a Sardinian family. Multiple Sclerosis and Related Disorders, 2018, 25, 73-76.	2.0	4
130	Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. Acta Neurologica Scandinavica, 2018, 138, 447-453.	2.1	4
131	Digital epidemiology confirms a latitude gradient of MS in France. Multiple Sclerosis and Related Disorders, 2018, 20, 129-131.	2.0	6
132	Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood. Journal of the Neurological Sciences, 2018, 384, 58-60.	0.6	2
133	Long-term safety and tolerability of glatiramer acetate 20 mg in the treatment of relapsing forms of multiple sclerosis. Expert Opinion on Drug Safety, 2017, 16, 247-255.	2.4	24
134	Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: A clinical-imaging evaluation. Multiple Sclerosis Journal, 2017, 23, 577-587.	3.0	26
135	Subcutaneous interferon Î²-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 285-294.	1.9	38
136	The first year after diagnosis: psychological impact on people with multiple sclerosis. Psychology, Health and Medicine, 2017, 22, 1063-1071.	2.4	23
137	Typical and atypical pathology in primary progressive aphasia variants. Annals of Neurology, 2017, 81, 430-443.	5.3	288
138	Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1864-1874.	3.0	48
139	Evaluation of an optimized [ <sup>18</sup> F]fluoro-2-deoxy-2-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders. European Journal of Neurology, 2017, 24, 687.	3.3	40
140	DT MRI microstructural cortical lesion damage does not explain cognitive impairment in MS. Multiple Sclerosis Journal, 2017, 23, 1918-1928.	3.0	13
141	Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case. Multiple Sclerosis Journal, 2017, 23, 1558-1561.	3.0	4
142	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	5.3	34
143	Structural brain abnormalities in patients with vestibular migraine. Journal of Neurology, 2017, 264, 295-303.	3.6	42
144	Structural and functional brain signatures of C9orf72 in motor neuron disease. Neurobiology of Aging, 2017, 57, 206-219.	3.1	54

#	ARTICLE	IF	CITATIONS
145	Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 454-461.	2.1	18
146	Moyamoya disease mimicking the first attack of multiple sclerosis. <i>Journal of Neurology</i> , 2017, 264, 1005-1007.	3.6	2
147	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 221-234.	27.0	1,322
148	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 209-220.	27.0	1,324
149	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsingâ€“remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). <i>Journal of Neurology</i> , 2017, 264, 2436-2449.	3.6	44
150	Brain network connectivity differs in early-onset neurodegenerative dementia. <i>Neurology</i> , 2017, 89, 1764-1772.	1.1	90
151	Cerebrospinal Fluid Amyloid-Î² 42, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 183-200.	2.6	31
152	â€“Progressive MS â€“ macro viewsâ€™: The need for novel clinical trial paradigms to enable drug development for progressive MS. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1649-1655.	3.0	3
153	Fluid biomarker and electrophysiological outcome measures for progressive MS trials. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1600-1613.	3.0	28
154	The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017, 3, 205521731773280.	1.0	22
155	Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. <i>Brain</i> , 2017, 140, 2814-2819.	7.6	51
156	MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients. <i>Neurology</i> , 2017, 89, 1265-1273.	1.1	13
157	Weight gain after subthalamic nucleus deep brain stimulation in Parkinsonâ€™s disease is influenced by dyskinesiasâ€™ reduction and electrodesâ€™ position. <i>Neurological Sciences</i> , 2017, 38, 2123-2129.	1.9	19
158	Benefitâ€“Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. <i>Drugs</i> , 2017, 77, 1755-1768.	10.9	49
159	Structural connectivityâ€“defined thalamic subregions have different functional connectivity abnormalities in multiple sclerosis patients: Implications for clinical correlations. <i>Human Brain Mapping</i> , 2017, 38, 6005-6018.	3.6	40
160	Multimodal structural MRI in the diagnosis of motor neuron diseases. <i>NeuroImage: Clinical</i> , 2017, 16, 240-247.	2.7	55
161	Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice. <i>Journal of the Neurological Sciences</i> , 2017, 383, 166-168.	0.6	29
162	Pediatric versus adult MS: similar or different?. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, .	1.1	32

#	ARTICLE	IF	CITATIONS
163	Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two cases. <i>Neurological Sciences</i> , 2017, 38, 361-364.	1.9	8
164	Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. <i>Neurological Sciences</i> , 2017, 38, 53-59.	1.9	25
165	Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1194-1203.	3.0	53
166	Brain plasticity in Parkinson's disease with freezing of gait induced by action observation training. <i>Journal of Neurology</i> , 2017, 264, 88-101.	3.6	101
167	Action observation training modifies brain gray matter structure in healthy adult individuals. <i>Brain Imaging and Behavior</i> , 2017, 11, 1343-1352.	2.1	12
168	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 257-266.	0.8	41
169	Mapping face encoding using functional MRI in multiple sclerosis across disease phenotypes. <i>Brain Imaging and Behavior</i> , 2017, 11, 1238-1247.	2.1	5
170	Evolving concepts in the treatment of relapsing multiple sclerosis. <i>Lancet, The</i> , 2017, 389, 1347-1356.	13.7	252
171	The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2017, 8, 433.	2.4	58
172	Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients. <i>Scientific Reports</i> , 2017, 7, 40136.	3.3	38
173	Laquinimod Safety Profile. <i>International Journal of MS Care</i> , 2017, 19, 16-24.	1.0	15
174	Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis. <i>Multiple Sclerosis International</i> , 2016, 2016, 1-9.	0.8	18
175	MRI and neurophysiological measures to predict course, disability and treatment response in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2016, 29, 243-253.	3.6	29
176	Progressive ataxia in a natalizumab-treated multiple sclerosis patient: the dark side of JC virus infection. <i>European Journal of Neurology</i> , 2016, 23, e39-40.	3.3	2
177	Structural brain correlates of cognitive and behavioral impairment in MND. <i>Human Brain Mapping</i> , 2016, 37, 1614-1626.	3.6	84
178	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 944-951.	1.9	88
179	Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1495-1508.	2.6	24
180	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1386-1396.	3.0	118

#	ARTICLE	IF	CITATIONS
181	Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: A case report. <i>Journal of the Neurological Sciences</i> , 2016, 361, 184-186.	0.6	2
182	Progressive MS Alliance Industry Forum: Maximizing Collective Impact To Enable Drug Development. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 808-810.	8.7	11
183	Optic neuritis in multiple sclerosis. <i>Neurology</i> , 2016, 87, 338-339.	1.1	1
184	Amyloid- $\beta$ deposition and regional grey matter atrophy rates in dementia with Lewy bodies. <i>Brain</i> , 2016, 139, 2740-2750.	7.6	68
185	Abnormalities of the executive control network in multiple sclerosis phenotypes: An fMRI effective connectivity study. <i>Human Brain Mapping</i> , 2016, 37, 2293-2304.	3.6	29
186	Cognitive impairment in progressive supranuclear palsy-Richardson's syndrome is related to white matter damage. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 65-71.	2.2	17
187	Surrogate Markers in Multiple Sclerosis. , 2016, , 163-187.		0
188	A review of recent literature on functional MRI and personal experience in two cases of definite vestibular migraine. <i>Neurological Sciences</i> , 2016, 37, 1399-1402.	1.9	27
189	Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life "A post hoc analysis of the TEMSO and TOWER studies. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 7, 33-40.	2.0	32
190	Clinical Pregenetic Screening for Stroke Monogenic Diseases. <i>Stroke</i> , 2016, 47, 1702-1709.	2.0	34
191	Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1506-1508.	3.0	41
192	Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1315-1326.	3.0	62
193	Assessing response to interferon- $\beta$ in a multicenter dataset of patients with MS. <i>Neurology</i> , 2016, 87, 134-140.	1.1	98
194	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. <i>Journal of Neurology</i> , 2016, 263, 1727-1735.	3.6	45
195	Searching for the neural basis of reserve against memory decline: intellectual enrichment linked to larger hippocampal volume in multiple sclerosis. <i>European Journal of Neurology</i> , 2016, 23, 39-44.	3.3	33
196	Impaired functional integration in multiple sclerosis: a graph theory study. <i>Brain Structure and Function</i> , 2016, 221, 115-131.	2.3	122
197	Noninvasive Neuromodulation in Poststroke Gait Disorders. <i>Neurorehabilitation and Neural Repair</i> , 2016, 30, 71-82.	2.9	49
198	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 574-584.	10.2	266

#	ARTICLE	IF	CITATIONS
199	Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue. Multiple Sclerosis Journal, 2016, 22, 1144-1153.	3.0	55
200	Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2016, 15, 373-381.	10.2	150
201	Reading, writing, and reserve: Literacy activities are linked to hippocampal volume and memory in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1621-1625.	3.0	22
202	Brain MR Imaging in Patients with Lower Motor Neuronâ€“Predominant Disease. Radiology, 2016, 280, 545-556.	7.3	32
203	MR Imaging of Brachial Plexus and Limb-Girdle Muscles in Patients with Amyotrophic Lateral Sclerosis. Radiology, 2016, 279, 553-561.	7.3	32
204	Long-term (up to 4.5â€“years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 468-475.	1.9	137
205	Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 628-640.	3.0	28
206	Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Multiple Sclerosis Journal, 2016, 22, 511-519.	3.0	76
207	Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 292-301.	3.0	16
208	Following the Spreading of Brain Structural Changes in Alzheimerâ€™s Disease: A Longitudinal, Multimodal MRI Study. Journal of Alzheimer's Disease, 2015, 47, 995-1007.	2.6	43
209	Ceruloplasmin functional changes in Parkinsonâ€™s disease-cerebrospinal fluid. Molecular Neurodegeneration, 2015, 10, 59.	10.8	35
210	Brain structural and functional connectivity in <sc>P</sc>arkinson's disease with freezing of gait. Human Brain Mapping, 2015, 36, 5064-5078.	3.6	154
211	Hippocampalâ€“<sc>DMN</sc> disconnectivity in <sc>MS</sc> is related to <sc>WM</sc> lesions and depression. Human Brain Mapping, 2015, 36, 5051-5063.	3.6	58
212	The Communication of Multiple Sclerosis Diagnosis: The Patientsâ€™ Perspective. Multiple Sclerosis International, 2015, 2015, 1-7.	0.8	7
213	Switching from natalizumab to fingolimod. Neurology, 2015, 85, 29-39.	1.1	110
214	White Matter Degeneration in Atypical Alzheimer Disease. Radiology, 2015, 277, 162-172.	7.3	55
215	White matter microstructure abnormalities in pediatric migraine patients. Cephalalgia, 2015, 35, 1278-1286.	3.9	42
216	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	3.0	249

#	ARTICLE	IF	CITATIONS
217	Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. Multiple Sclerosis Journal, 2015, 21, 189-197.	3.0	56
218	Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions. Multiple Sclerosis Journal, 2015, 21, 956-959.	3.0	21
219	Differentiation between Subtypes of Primary Progressive Aphasia by Using Cortical Thickness and Diffusion-Tensor MR Imaging Measures. Radiology, 2015, 276, 219-227.	7.3	34
220	Pharmacogenetic influence of eNOS gene variant on endothelial and glucose metabolism responses to L-arginine supplementation: Post hoc analysis of the L-arginine trial. Metabolism: Clinical and Experimental, 2015, 64, 1582-1591.	3.4	7
221	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain, 2015, 138, 3275-3286.	7.6	76
222	Thrombolysis with rt-PA for an ischemic stroke in boy treated with Fontan operation. Journal of Pediatric Neurology, 2015, 09, 497-500.	0.2	0
223	Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. Journal of Neurology, 2015, 262, 2466-2471.	3.6	4
224	Elevated body temperature is linked to fatigue in an Italian sample of relapsingâ€“remitting multiple sclerosis patients. Journal of Neurology, 2015, 262, 2440-2442.	3.6	22
225	SativexÂ® and clinicalâ€“neurophysiological measures of spasticity in progressive multiple sclerosis. Journal of Neurology, 2015, 262, 2520-2527.	3.6	47
226	A multimodal neuroimaging study of a case of crossed nonfluent/agrammatic primary progressive aphasia. Journal of Neurology, 2015, 262, 2336-2345.	3.6	24
227	Oral corticosteroids for multiple sclerosis relapse. Lancet, The, 2015, 386, 937-939.	13.7	7
228	Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromes. Journal of Neuroimmunology, 2015, 289, 62-67.	2.3	20
229	Relapses in patients treated with fingolimod after previous exposure to natalizumab. Multiple Sclerosis Journal, 2015, 21, 786-790.	3.0	26
230	Efficacy of subcutaneous interferon Â-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 647-653.	1.9	23
231	Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 851-858.	1.9	101
232	Position and practical use of fingolimod in Europe. Clinical and Experimental Neuroimmunology, 2014, 5, 19-33.	1.0	6
233	Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis Journal, 2014, 20, 705-716.	3.0	295
234	Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. Multiple Sclerosis and Related Disorders, 2014, 3, 147-155.	2.0	57

#	ARTICLE	IF	CITATIONS
235	Deep Repetitive Transcranial Magnetic Stimulation With H-coil on Lower Limb Motor Function in Chronic Stroke: A Pilot Study. Archives of Physical Medicine and Rehabilitation, 2014, 95, 1141-1147.	0.9	43
236	Clinical and MRI correlates of disease progression in a case of nonfluent/agrammatic variant of primary progressive aphasia due to progranulin (GRN) Cys157LysfsX97 mutation. Journal of the Neurological Sciences, 2014, 342, 167-172.	0.6	20
237	Excitatory Deep Repetitive Transcranial Magnetic Stimulation With H-coil as Add-on Treatment of Motor Symptoms in Parkinson's Disease: An Open Label, Pilot Study. Brain Stimulation, 2014, 7, 297-300.	1.6	38
238	Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. Journal of Neurology, 2014, 261, 267-276.	3.6	117
239	Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2014, 13, 247-256.	10.2	476
240	Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Multiple Sclerosis Journal, 2014, 20, 147-155.	3.0	94
241	Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 862-870.	3.0	11
242	Resting state functional connectivity alterations in primary lateral sclerosis. Neurobiology of Aging, 2014, 35, 916-925.	3.1	41
243	Multiple sclerosis progression is not associated with birth timing in Italy. Journal of the Neurological Sciences, 2014, 346, 194-196.	0.6	1
244	Neuropsychological features in childhood and juvenile multiple sclerosis. Neurology, 2014, 83, 1432-1438.	1.1	227
245	Autologous Bone Marrow Transplantation for the Treatment of Multiple Sclerosis. Current Neurology and Neuroscience Reports, 2014, 14, 478.	4.2	24
246	Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology, 2014, 261, 1781-1788.	3.6	23
247	Peripheral nerve morphogenesis induced by scaffold micropatterning. Biomaterials, 2014, 35, 4035-4045.	11.4	39
248	Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2014, 13, 977-986.	10.2	254
249	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.1	2,344
250	Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology, The, 2014, 13, 257-267.	10.2	194
251	Disrupted brain connectome in semantic variant of primary progressive aphasia. Neurobiology of Aging, 2014, 35, 2646-2655.	3.1	74
252	Intrahemispheric and interhemispheric structural network abnormalities in PLS and ALS. Human Brain Mapping, 2014, 35, 1710-1722.	3.6	76



#	ARTICLE	IF	CITATIONS
253	Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. Journal of Neurology, 2013, 260, 2472-2480.	3.6	35
254	Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology, 2013, 260, 2023-2032.	3.6	82
255	Treatment of cognitive impairment in multiple sclerosis: position paper. Journal of Neurology, 2013, 260, 1452-1468.	3.6	189
256	MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. Journal of Neurology, 2013, 260, 1136-1146.	3.6	46
257	Brain atrophy and lesion load predict long term disability in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1082-1091.	1.9	267
258	Italian multicentre observational study of the prevalence of CCSVI in multiple sclerosis (CoSMo). Tj ETQq0 0 0 rgBT /Qverlock 10 Tf 50 54	1.9	16
259	Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. Multiple Sclerosis Journal, 2013, 19, 1084-1094.	3.0	43
260	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Multiple Sclerosis Journal, 2013, 19, 1074-1083.	3.0	87
261	Disease-modifying treatments for progressive multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1428-1436.	3.0	44
262	Cladribine tablets for the treatment of relapsing&quot;remitting multiple sclerosis. Expert Opinion on Pharmacotherapy, 2013, 14, 123-136.	1.8	24
263	Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of Tuberous Sclerosis Complex. Neuropharmacology, 2013, 67, 1-7.	4.1	40
264	Functional end-plate recovery in long-term botulinum toxin therapy of hemifacial spasm: a nerve conduction study. Neurological Sciences, 2013, 34, 209-215.	1.9	5
265	Extramotor Damage Is Associated with Cognition in Primary Lateral Sclerosis Patients. PLoS ONE, 2013, 8, e82017.	2.5	33
266	Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Annals of Neurology, 2012, 72, 610-624.	5.3	277
267	Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor. American Journal of Pathology, 2012, 180, 267-274.	3.8	127
268	Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis. New England Journal of Medicine, 2012, 366, 1000-1009.	27.0	329
269	Sturge-Weber syndrome with an unusual onset in the sixth decade: a case report. Neurological Sciences, 2012, 33, 949-950.	1.9	5
270	Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurology, The, 2012, 11, 33-41.	10.2	185

#	ARTICLE	IF	CITATIONS
271	Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. Multiple Sclerosis and Related Disorders, 2012, 1, 49-54.	2.0	29
272	Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRibine Tablets) Trial. Multiple Sclerosis and Related Disorders, 2012, 1, 55-61.	3.0	109
273	A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex <sup>®</sup> ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology, 2011, 18, 1122-1131.	3.3	364
274	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurology, The, 2011, 10, 520-529.	10.2	204
275	Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurological Sciences, 2011, 31, 299-302.	1.9	52
276	Natalizumab: state of the art and open questions. Neurological Sciences, 2011, 31, 313-315.	1.9	2
277	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group of the Italian Neurological Society. Neurological Sciences, 2011, 32, 351-358.	1.9	17
278	A fatal case of Churg-Strauss syndrome presenting with acute polyneuropathy mimicking Guillain-Barré syndrome. Neurological Sciences, 2011, 32, 937-940.	1.9	10
279	Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2011, 365, 1293-1303.	27.0	842
280	Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1344-1350.	1.9	80
281	Neurophysiological correlates of cognitive disturbances in multiple sclerosis. Neurological Sciences, 2010, 31, 249-253.	1.9	17
282	Effects of disease modifying treatments on cognitive dysfunction in multiple sclerosis. Neurological Sciences, 2010, 31, 261-264.	1.9	19
283	Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Annals of Neurology, 2010, 68, 409-411.	5.3	40
284	Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2010, 362, 402-415.	27.0	1,983
285	The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology, 2010, 75, 2121-2128.	1.1	166
286	A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2010, 362, 416-426.	27.0	791
287	Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Multiple Sclerosis Journal, 2010, 16, 197-207.	3.0	149
288	Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Multiple Sclerosis Journal, 2010, 16, 1360-1366.	3.0	53

#	ARTICLE	IF	CITATIONS
289	A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. <i>Neurology</i> , 2009, 73, 1842-1848.	1.1	74
290	250 µg or 500 µg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. <i>Lancet Neurology</i> , The, 2009, 8, 889-897.	10.2	377
291	Real-life impact of early interferon $\beta$ 2 therapy in relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2009, 66, 513-520.	5.3	132
292	Corpus callosum damage and cognitive dysfunction in benign MS. <i>Human Brain Mapping</i> , 2009, 30, 2656-2666.	3.6	99
293	Mitoxantrone: benefits and risks in multiple sclerosis patients. <i>Neurological Sciences</i> , 2009, 30, 167-170.	1.9	69
294	Treatment of multiple sclerosis: role of natalizumab. <i>Neurological Sciences</i> , 2009, 30, 155-158.	1.9	22
295	Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. <i>Journal of the Neurological Sciences</i> , 2009, 286, 109-113.	0.6	23
296	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2009, 374, 1503-1511.	13.7	551
297	Definition of responder: introduction. <i>Neurological Sciences</i> , 2008, 29, 209-210.	1.9	1
298	Induction vs. escalating therapy in Multiple Sclerosis: practical implications. <i>Neurological Sciences</i> , 2008, 29, 253-255.	1.9	35
299	Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. <i>Lancet</i> , The, 2008, 371, 2085-2092.	13.7	265
300	Clinically isolated syndrome: the rationale for early treatment. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 234-235.	2.5	16
301	Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2006, 355, 1124-1140.	27.0	996
302	MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction. <i>Journal of the Neurological Sciences</i> , 2006, 245, 111-116.	0.6	68
303	Early treatment. <i>Neurological Sciences</i> , 2006, 27, s8-s12.	1.9	12
304	Extracorporeal phototherapy in multiple sclerosis. <i>Neurological Sciences</i> , 2006, 27, 3-4.	1.9	2
305	Understanding fatigue in multiple sclerosis: new insights in causes and assessment. <i>Neurological Sciences</i> , 2006, 27, s304-s306.	1.9	5
306	Italian Multiple Sclerosis Database Network. <i>Neurological Sciences</i> , 2006, 27, s358-s361.	1.9	18

#	ARTICLE	IF	CITATIONS
307	Loss of glial fibrillary acidic protein (GFAP) impairs Schwann cell proliferation and delays nerve regeneration after damage. <i>Journal of Cell Science</i> , 2006, 119, 3981-3993.	2.0	174
308	Imaging Spinal Cord Damage in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2005, 15, 297-304.	2.0	13
309	Evidence for use of glatiramer acetate in multiple sclerosis. <i>Lancet Neurology</i> , The, 2005, 4, 75-76.	10.2	8
310	Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. <i>Neurology</i> , 2004, 62, 1432-1434.	1.1	113
311	Multiple sclerosis: pseudotumoral forms. <i>Neurological Sciences</i> , 2004, 25, s374-s379.	1.9	43
312	Simple and complex movement-associated functional MRI changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. <i>Human Brain Mapping</i> , 2004, 21, 108-117.	3.6	96
313	Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2004, 364, 1489-1496.	13.7	246
314	Cognitive dysfunction in patients with mildly disabling relapsingâ€“remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. <i>Journal of the Neurological Sciences</i> , 2002, 195, 103-109.	0.6	208
315	A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. <i>Journal of Neurology</i> , 2002, 249, 1370-1377.	3.6	151
316	<i>Neurophysiology</i> , , 2002, , 25-33.		0
317	The role of non-conventional MR techniques to study multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2001, 186, S3-S9.	0.6	15
318	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. <i>Lancet</i> , The, 2001, 357, 1576-1582.	13.7	1,025
319	Physiopathology and treatment of fatigue in multiple sclerosis. <i>Journal of Neurology</i> , 2001, 248, 174-179.	3.6	165
320	European/Canadian multicenter, doubleâ€“blind, randomized, placeboâ€“controlled study of the effects of glatiramer acetate on magnetic resonance imagingâ€“measured disease activity and burden in patients with relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2001, 49, 290-297.	5.3	695
321	Effects of seasons on magnetic resonance imagingâ€“measured disease activity in patients with multiple sclerosis. <i>Annals of Neurology</i> , 2001, 49, 415-416.	5.3	32
322	European/Canadian multicenter, doubleâ€“blind, randomized, placeboâ€“controlled study of the effects of glatiramer acetate on magnetic resonance imagingâ€“measured disease activity and burden in patients with relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2001, 49, 290-297.	5.3	19
323	European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imagingâ€“measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. <i>Annals of Neurology</i> , 2001, 49, 290-7.	5.3	224
324	Whole brain volume changes in patients with progressive MS treated with cladribine. <i>Neurology</i> , 2000, 55, 1714-1718.	1.1	124

#	ARTICLE	IF	CITATIONS
325	Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2000, 247, 960-965.	3.6	51
326	MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. <i>Journal of Neurology</i> , 2000, 247, 506-509.	3.6	122
327	Prognosis-modifying therapy in multiple sclerosis. <i>Neurological Sciences</i> , 2000, 21, S893-S899.	1.9	6
328	Magnetization transfer imaging to monitor the evolution of MS. <i>Neurology</i> , 2000, 55, 940-946.	1.1	145
329	Chapter 45 Electrophysiological correlates of dementia. <i>Supplements To Clinical Neurophysiology</i> , 2000, 53, 331-336.	2.1	2
330	Electroencephalographic coherence analysis in multiple sclerosis: correlation with clinical, neuropsychological, and MRI findings. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 192-198.	1.9	101
331	Assessment of the damage of the cerebral hemispheres in MS using neuroimaging techniques. <i>Journal of the Neurological Sciences</i> , 2000, 172, S63-S66.	0.6	21
332	Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. <i>Neurology</i> , 1999, 52, 588-588.	1.1	241
333	Correlation between enhancing lesion number and volume on standard and triple dose gadolinium-enhanced brain MRI scans from patients with multiple sclerosis. <i>Magnetic Resonance Imaging</i> , 1999, 17, 985-988.	1.8	8
334	A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions. <i>Journal of Neurology</i> , 1999, 246, 97-106.	3.6	9
335	Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 1999, 171, 130-134.	0.6	15
336	A multiparametric MRI study of frontal lobe dementia in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1999, 171, 135-144.	0.6	48
337	Introduction. <i>Neurological Sciences</i> , 1999, 20, S227-S228.	1.9	0
338	Neurophysiological imaging techniques in dementia. <i>Neurological Sciences</i> , 1999, 20, S265-S269.	1.9	10
339	The Italian multicentre study on the prevalence of distal symmetric polyneuropathy: correlation between clinical variables and nerve conduction parameters. <i>Italian Diabetic Neuropathy Committee. Electroencephalography and Clinical Neurophysiology Supplement</i> , 1999, 50, 546-52.	0.0	2
340	Proinflammatory cytokines regulate antigen-independent T-cell Activation by two separate calcium-signaling pathways in multiple sclerosis patients. <i>Annals of Neurology</i> , 1998, 43, 340-349.	5.3	44
341	Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. <i>Annals of Neurology</i> , 1998, 43, 809-814.	5.3	356
342	Event-Related desynchronization to contingent negative variation and Self-Paced movement paradigms in Parkinson's disease. <i>Movement Disorders</i> , 1998, 13, 653-660.	3.9	61

#	ARTICLE	IF	CITATIONS
343	Neuromyotonia, systemic lupus erythematosus and acetylcholine-receptor antibodies. Journal of Neurology, 1998, 245, 182-185.	3.6	3
344	Treatment of chronic inflammatory demyelinating polyneuropathy. Italian Journal of Neurological Sciences, 1998, 19, 261-269.	0.1	1
345	EEG correlates of cognitive impairment in MS. Italian Journal of Neurological Sciences, 1998, 19, S413-S417.	0.1	4
346	Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology, 1998, 50, 1601-1608.	1.1	253
347	Neurophysiological and cognitive markers of disease evolution in multiple sclerosis. Multiple Sclerosis Journal, 1998, 4, 260-265.	3.0	25
348	Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. American Journal of Neuroradiology, 1998, 19, 223-9.	2.4	51
349	Intravenous immunoglobulin treatment in multifocal motor neuropathy and other chronic immune-mediated neuropathies. Multiple Sclerosis Journal, 1997, 3, 93-97.	3.0	6
350	Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain, 1997, 120, 2059-2069.	7.6	1,077
351	Axonal neuropathy associated with interferon- $\alpha$ treatment for hepatitis C: HLA-DR immunoreactivity in Schwann cells. Acta Neuropathologica, 1997, 94, 504-508.	7.7	24
352	Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. Journal of Neurology, 1997, 244, 266-270.	3.6	153
353	Functional Basis of Memory Impairment in Multiple Sclerosis: A [18F]FDG PET Study. NeuroImage, 1996, 4, 87-96.	4.2	127
354	Interferon beta treatment in multiple sclerosis: the European clinical trials. Multiple Sclerosis Journal, 1996, 1, 317-320.	3.0	0
355	Brain MRI follow-up of patients with persistent isolated optic neuritis. European Journal of Neurology, 1996, 3, 36-39.	3.3	2
356	A spinal cord MRI study of benign and secondary progressive multiple sclerosis. Journal of Neurology, 1996, 243, 502-505.	3.6	115
357	Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology, 1996, 46, 379-384.	1.1	124
358	Quantitative assessment of MRI lesion load in multiple sclerosis: A comparison of conventional spin-echo with fast fluidattenuated inversion recovery. Brain, 1996, 119, 1349-1355.	7.6	164
359	Clinical utility of evoked potentials in patients infected with human immunodeficiency virus. Electroencephalography and Clinical Neurophysiology Supplement, 1996, 46, 85-93.	0.0	2
360	Neurophysiologic Studies and Cognitive Function in Congenital Hypothyroid Children. Pediatric Research, 1995, 37, 736-740.	2.3	20

#	ARTICLE	IF	CITATIONS
361	A Magnetization Transfer Imaging Study of Normal-Appearing White Matter in Multiple Sclerosis. <i>Neurology</i> , 1995, 45, 478-482.	1.1	353
362	Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1995, 132, 222-227.	0.6	167
363	Heterogeneity of autoantibodies in stiffâ€man syndrome. <i>Annals of Neurology</i> , 1993, 34, 57-64.	5.3	121
364	Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1993, 115, S66-S73.	0.6	95
365	Brain Stem Magnetic Resonance Imaging and Evoked Potential Studies of Symptomatic Multiple Sclerosis Patients. <i>European Neurology</i> , 1993, 33, 232-237.	1.4	27
366	Correlation between multimodal evoked potentials and magnetic resonance imaging in multiple sclerosis. <i>Journal of Neurology</i> , 1989, 236, 4-8.	3.6	40
367	Visual evoked potentials in diabetic teen-agers: influence of metabolic control and relationship with peripheral neuropathy. <i>Metabolic, Pediatric, and Systemic Ophthalmology</i> , 1986, 9, 85-7.	0.0	7
368	Time-frequency analysis of event-related brain potentials. , 0, , .		0